Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-O-1002 in nAMD
NCT05390840Phase 2Recruiting
- Sponsor
- TheratOcular Biotek
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MG-O-1002 in neovascular age-related macular degeneration (NVAMD), sponsored by TheratOcular Biotek. Started Aug 2022; status: recruiting.
02
Drugs
MG-O-1002
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05390840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390840.